目的：研究氯吡格雷联合重组链激酶溶栓治疗急性心肌梗死的临床疗效，并探讨安全性。方法选取我院自2012年5月至2013年11月期间收治的急性心肌梗死患者122例作为研究对象，随机分为对照组和实验组，每组患者61例，对照组61例患者采用重组链激酶溶栓治疗法进行治疗，实验组61例患者则采用氯吡格雷联合重组链激酶溶栓治疗法进行治疗，比较两组患者的临床治疗效果。结果实验组患者的治疗效果显著大于对照组，且组间差异明显，具有统计学意义(P<0．05)。两组患者的不良反应发生情况无差异(P>0．05)，不具有统计学意义。结论氯吡格雷联合重组链激酶溶栓治疗急性心肌梗死的疗效显著，临床价值较高。%Objective The clinical efficacy of clopidogrel combined with recombinant streptokinase thrombolytic therapy for acute myocardial infarction, and the method of security. Methods in our hospital from 2012 May to the period of acute myocardial infarction in 2013 November admitted 122 patients as the re-search object,randomly divided into the control group and the experimental group,61 cases of patients in each group,the control group of 61 patients using recombinant streptokinase thrombolytic therapy treatment,experi-mental group of 61 patients using recombinant streptokinase thrombolytic therapy with clopidogrel for treat-ment,compared two groups of patients with clinical curative effect. Results Patients in the experimental group and the treatment effect is significantly greater than the control group,and the difference between groups was statistically significant(P<0. 05). Two groups of patients with adverse reactions occurrence(P>0. 05), little difference was not statistically significant. Conclusion Efficacy of clopidogrel combined with recombi-nant streptokinase thrombolytic therapy for acute myocardial infarction significantly,higher clinical value.
展开▼
